A recent study published in Science Advances highlights the role of NAD+ in modulating alternative RNA splicing associated with tauopathy, a hallmark of Alzheimer’s disease (AD). This research suggests that NAD+ can reverse cognitive deficits and restore splicing fidelity through its effects on the gene _EVA1C_.

Understanding Alternative Splicing

Alternative splicing is a critical biological process where different combinations of exons are joined together to form various isoforms of proteins, impacting their function. As individuals age, the efficiency of this process tends to decline, leading to potential dysregulation observed in neurodegenerative diseases.

  • Exons: Segments of DNA that are transcribed into mature RNA and translated into proteins.
  • Introns: Non-coding segments that are removed during RNA processing.
  • Isoforms: Different forms of proteins produced from the same gene due to alternative splicing.

Exploring the Role of NAD+

The study investigates how NAD+, a vital metabolite involved in cellular energy production, affects alternative splicing and thereby cognitive function. Previous research has hinted at NAD+’s therapeutic potential in ameliorating AD symptoms, yet the underlying mechanisms have remained elusive.

“Preliminary studies have shown that supplementation with NAD⁺ precursors can offer therapeutic benefits in AD animal models and early clinical trials. However, the molecular mechanisms behind these benefits remain largely unclear.” – Alice Ruixue Ai, First Author

Methodology: From Worms to Mice

The researchers initially utilized genetically modified C. elegans nematode models to assess the impact of NAD+ on splicing fidelity. The nematodes were engineered to express a human tau variant, and the results indicated that:

  1. Splicing Errors: Aging tau worms exhibited increased splicing errors.
  2. Memory Deficits: Treated worms showed memory-like defects and shorter lifespans.
  3. NAD+ Impact: Treatment with nicotinamide riboside (NR), a precursor of NAD+, enhanced splicing fidelity and improved both memory and lifespan.

Following these findings, similar experiments were conducted with tau.P301S mouse models, confirming that NR supplementation could normalize disrupted splicing patterns. The researchers focused on understanding the molecular pathways through RNA sequencing analysis, identifying key genes involved in RNA processing.

Table: Key Findings from the Research

Feature Observations Significance
Splicing Fidelity Increased errors in aging tau models Critical for protein functionality
Gene Expression Altered expression of _Eva1c_ Linked to neuronal health
NAD+ Treatment Restored splicing and cognition Potential therapy for AD

Manipulating EVA1C: The Path Forward

The study further manipulated the expression of _Eva1c_ in both mice and worms, establishing that these effects on longevity and cognition were indeed reliant on _Eva1c_. In experiments involving AAV-based tauopathy models, the researchers found that manipulating the isoform ratios of _Eva1c_ could replicate the cognitive improvements observed with NAD+ treatment.

Table: Summary of Experimental Results

Model Experiment Outcome
C. elegans NR treatment with EVA1C knockdown Loss of NR benefits
Mice (Tau.P301S) NMN treatment with EVA1C manipulation Cognitive restoration dependent on EVA1C
RNA Sequencing Comparison of AD and control tissue Altered EVA1C expression in AD brains

This research establishes a clear link between NAD+ metabolism, alternative splicing of _EVA1C_, and cognitive functions, suggesting that maintaining NAD+ levels could delay cognitive decline and provide avenues for innovative therapeutic strategies against Alzheimer’s disease.

Conclusions and Future Directions

The study’s findings prompt further investigation into potential treatments focusing on the preservation of NAD+ levels, alongside therapies targeting splicing mechanisms. The implications of _EVA1C_ dysregulation in Alzheimer’s pathology advocate for future research to evaluate combination therapies aimed at enhancing RNA splicing integrity while mitigating cognitive decline.

Literature Cited

[1] Ai, R., Mao, L., Jin, X., Campos-Marques, C., Zhang, S. Q., Pan, J., … & Fang, E. F. (2025). NAD+ reverses Alzheimer’s neurological deficits via regulating differential alternative RNA splicing of EVA1C. Science Advances, 11(45), eady9811.

[2] Bhadra, M., et al. (2020). Alternative splicing in aging and longevity. Human Genetics, 139(3), 357-369.

[3] Nikom, D., & Zheng, S. (2023). Alternative splicing in neurodegenerative disease and the promise of RNA therapies. Nature Reviews Neuroscience, 24(8), 457-473.

[4] Hou, Y., et al. (2018). NAD+ supplementation normalizes key Alzheimer’s features and DNA damage responses. Proceedings of the National Academy of Sciences, 115(8), E1876-E1885.

To support our ongoing efforts in independent journalism and to continue providing free educational content, we encourage contributions from the community. Every donation helps sustain our future initiatives.